Merck KGaA Completes $3.4 Billion Acquisition of SpringWorks Therapeutics Boosting Rare Oncology Portfolio
German pharmaceutical giant Merck KGaA (ETR: MRK) has completed its USD 3.4 billion (EUR 3...
SpringWorks Therapeutics
Merck KGaA Nears Completion of $3.5 Billion Acquisition of SpringWorks Therapeutics
German pharmaceutical major Merck KGaA (ETR: MRK) is reportedly nearing the completion of its acquisition of...
BeiGene and SpringWorks Therapeutics Report Positive Phase Ib Results for Lifirafenib and Mirdametinib Combination
China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) and SpringWorks Therapeutics Inc., (NASDAQ: SWTX) have...